Semaglutide |
| Catalog No.GC31404 |
Semaglutide is an agonist of the human glucagon-like peptide-1 (GLP-1) receptor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 910463-68-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Semaglutide is a long-acting analogue of human glucagon-like peptide-1 and an agonist for the human glucagon-like peptide-1 (GLP-1) receptor. It reduces blood sugar, body weight and blood pressure and improves blood sugar control in adults with type 2 diabetes[1-2].
Semaglutide(900 nM; 24h) attenuated the LPS‑ and nigericin‑induced inflammatory response and LDH release by blocking NLRP3 inflammasome activation in BV2 cells[3]. Semaglutide(5nM; 30min) promoted expression of GLP1R and activated PKG/PKCε/ERK1/2 signaling pathway in H/R H9C2 cells[4].
Semaglutide(40 µg/kg once every 3 days；4weeks；s.q) showed significant anti-inflammatory effects and mitigated the ER stress in eWAT adipocytes of obese mice[5]. Semaglutide（30 nmol/kg/day ;i.p; 12 weeks）reduces body weight, improves glucose metabolism, inflammation and oxidative stress in obese mice[6]. Semaglutide(0.1 mg/kg; i. p ) reduced blood glucose and promoted glucose metabolism in the brain of 3xTg mice via the SIRT1 pathway[7].
References:
[1]. Frías JP, Davies MJ, et, al. SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
[2]. Chao AM, Tronieri JS, et, al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591.
[3]. Wang L, Ding J, et, al. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice. Int J Mol Med. 2021 Dec;48(6):219. doi: 10.3892/ijmm.2021.5052. Epub 2021 Oct 22. PMID: 34676876; PMCID: PMC8547541.
[4]. Zhu Q, Luo Y, et, al. Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway. Biochem Biophys Res Commun. 2023 Mar 5;647:1-8. doi: 10.1016/j.bbrc.2023.01.049. Epub 2023 Jan 17. PMID: 36706596.
[5]. Martins FF, Marinho TS, et, al. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct. 2022 Dec;40(8):903-913. doi: 10.1002/cbf.3751. Epub 2022 Sep 28. PMID: 36169111.
[6]. Pan X, Yang L, et, al. Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression. Mol Cell Biochem. 2023 Jun 15. doi: 10.1007/s11010-023-04784-2. Epub ahead of print. PMID: 37318712.
[7]. Wang ZJ, Li XR, et, al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023 Dec 1;240:109716. doi: 10.1016/j.neuropharm.2023.109716. Epub 2023 Sep 18. PMID: 37730113.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *